Consolidated Statements of Comprehensive Income - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Statement of Comprehensive Income [Abstract]
Net income before allocation to noncontrolling interests		$ 2,158	$ 31,407	$ 22,025
Foreign currency translation adjustments, net		452	(2,328)	(682)
Unrealized holding gains/(losses) on derivative financial instruments, net		626	1,444	526
Reclassification adjustments for (gains)/losses included in net income	[1]	(413)	(2,062)	134
Other comprehensive income (loss), derivatives qualifying as hedges, before tax, total		213	(618)	660
Unrealized holding gains/(losses) on available-for-sale securities, net		(121)	(1,306)	(355)
Reclassification adjustments for (gains)/losses included in net income	[2]	(141)	1,809	(30)
Other comprehensive income (loss), available-for-sale securities adjustment, before tax, total		(261)	502	(384)
Benefit plans: prior service (costs)/credits and other, net		(25)	(24)	116
Reclassification adjustments related to amortization of prior service costs and other, net		(117)	(129)	(154)
Reclassification adjustments related to curtailments of prior service costs and other, net		(15)	(12)	(75)
Other comprehensive income (loss), benefit plans, prior service (costs)/credits, before tax, total		(157)	(166)	(113)
Other comprehensive income/(loss), before tax		246	(2,609)	(519)
Tax provision/(benefit) on other comprehensive income/(loss)		(85)	(187)	71
Other comprehensive income/(loss), net of tax		331	(2,422)	(589)
Comprehensive income/(loss) before allocation to noncontrolling interests		2,488	28,985	21,435
Less: Comprehensive income/(loss) attributable to noncontrolling interests		26	20	43
Comprehensive income/(loss) attributable to Pfizer Inc.		$ 2,462	$ 28,965	$ 21,393

[1] Reclassified into Other (income)/deductions—net and Cost of sales. See Note 7E.

[2] Reclassified into Other (income)/deductions—net.